Florence Releases 2021 State of Clinical Trial Technology Industry Report
Florence Healthcare has released its annual State of Clinical Trial Technology Industry Report. More than 230 clinical operations professionals across the drug development lifecycle participated in this year's report, revealing how they plan to invest in technology over the next three years.
Key findings from the survey conducted online in late November and early December include:
- 47% of sites and 36% of sponsors indicated they increased their 2020 technology budgets to reduce disruptions from COVID.
- 65% of sites intend to have an electronic investigator site file (eISF) in place by the end of 2020, and 47% expect to use eConsent.
- 90% of sites state that increasing their chances of being selected by a sponsor for a study is one of their primary reasons for investing in technology.
- 80% of sites and 83% of sponsors anticipate that most or all of their monitoring visits will be conducted remotely by 2023.
For more of the report’s findings, click here.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Novel Agent Shows Superiority Over Placebo in Reducing Monthly Migraine Days
September 5th 2024Lu AG09222 shows promise as first-in-class medication that prevents neurogenic inflammation, vasodilation, and parasympathetic lacrimation, which are considered to be surrogate markers of migraine attacks.
